|Sep 22, 2016||CTI BioPharma Granted 180 Day Extension By NASDAQ To Regain Compliance With Minimum Bid Price Rule|
|SEATTLE, Sept. 22, 2016 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA:CTIC) today announced that on September 20, 2016, the NASDAQ Listing Qualifications staff granted the Company an additional 180 calendar day period, or until March 20, 2017, to regain compliance with the Minimum Bid Price Rule. To do so, the bid price of the Company's common stock must close at or above $1.00 per share for a minimum of 10 consecutive trading days prior to that date.
About CTI BioPha... |
|Aug 29, 2016||CTI BioPharma Announces Top-Line Results From PERSIST-2 Phase 3 Trial Of Pacritinib For High-Risk Patients With Advanced Myelofibrosis|
|Trial demonstrates statistically significant improvement in spleen volume reduction (SVR) with pacritinib compared to best available therapy (BAT), including ruxolitinib
Oral pacritinib is the only JAK2 inhibitor evaluated in a randomized clinical trial in patients with thrombocytopenia (<100,000 platelets) to demonstrate a significant improvement in SVR, including in patients who had inadequate responses on marketed anti-JAK2 or failed prior anti-JAK2
SEATTLE, Aug. 29, 2016 /PRNewswi... |
|Aug 04, 2016||CTI BioPharma Reports Second Quarter 2016 Financial Results|
|SEATTLE, Aug. 4, 2016 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA:CTIC) today reported financial results for the second quarter ended June 30, 2016.
"The interest from oncologists generated by the Phase 3 PERSIST-1 long-term safety and efficacy results of pacritinib showing durable reduction in spleen volume and symptom burden including in patients that crossed over to pacritinib from best available therapy, presented at ASCO, supports our belief that pacritinib may play an important ... |
|Jun 07, 2016||Long-Term Follow Up Data For Pacritinib Presented At 2016 ASCO Annual Meeting|
|-72 week follow up of patients with myelofibrosis, including patients with baseline thrombocytopenia, show pacritinib treatment led to durable reductions in spleen volume and symptom burden-
SEATTLE, June 7, 2016 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA:CTIC) today announced long-term safety and efficacy results from the pivotal Phase 3 PERSIST-1 trial evaluating pacritinib versus best available therapy, excluding treatment with JAK2 inhibitors (BAT), in patients ... |
|May 19, 2016||CTI BioPharma Announces Presentations At The American Society Of Clinical Oncology Annual Meeting|
|- Four abstracts selected to be presented on pacritinib highlighting additional safety and long-term follow up data from Phase 3 PERSIST-1 trial -
SEATTLE, May 19, 2016 /PRNewswire/ -- CTI BioPharma Corp. (CTI) (NASDAQ and MTA:CTIC) today announced that data highlighting pacritinib, including additional safety and long-term follow up data from the Phase 3 PERSIST-1 clinical trial, will be presented at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting to be held June 3... |
|May 10, 2016||CTI BioPharma Reports First Quarter 2016 Financial Results|
|SEATTLE, May 10, 2016 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA:CTIC) today reported financial results for the first quarter ended March 31, 2016. "We continue to believe in the potential of pacritnib to help patients in need and are working to address the clinical hold on the pacritinib program," said James A. Bianco, M.D., President and Chief Executive Officer of CTI BioPharma. "While we work with the FDA to seek to address their recommendations for getting pacritinib off hold, we ha... |
|Apr 20, 2016||Preclinical Data Presented At AACR Indicate Pacritinib's Potential To Eradicate Therapy-Resistant Leukemia Stem Cells Residing In Bone Marrow Microenvironment|
|Additional pacritinib data also presented at AACR
SEATTLE, April 20, 2016 /PRNewswire/ -- CTI BioPharma Corp. (CTI) (NASDAQ and MTA:CTIC) today announced findings from an investigator-sponsored preclinical study indicating that pacritinib, an inhibitor of JAK2, FLT3, IRAK1 and CSF1R, may be effective in reducing survival of myelofibrosis and acute myeloid leukemia (AML) repopulating cells. Further, this study also demonstrated that the combination of pacritinib at low nanomolar concentratio... |
|Apr 13, 2016||CTI BioPharma Announces Presentations at the American Association of Cancer Research Annual Meeting|
|- Five abstracts selected to be presented on pacritinib -
SEATTLE, April 13, 2016 /PRNewswire/ -- CTI BioPharma Corp. (CTI) (NASDAQ and MTA:CTIC) today announced that data highlighting pacritinib, pixantrone and tosedostat will be presented at the upcoming American Association of Cancer Research (AACR) Annual Meeting to be held April 16-20 in New Orleans, LA. The abstracts are available on the AACR website at www.aacr.org.
Combinatorial strategies ... |
|Feb 16, 2016||CTI BioPharma Reports Fourth Quarter And Full Year 2015 Financial Results|
|SEATTLE, Feb. 16, 2016 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA:CTIC) today reported financial results for the fourth quarter and full year ended December 31, 2015.
"While we were disappointed and surprised by the FDA's decision to place pacritinib's IND on full clinical hold, our priority and sense of purpose has always been to do what is best for patients," said James A. Bianco, M.D., president and chief executive officer of CTI BioPharma."There remains a significant unmet medica... |
|Feb 09, 2016||CTI BioPharma Provides Update On Clinical Hold Of Investigational Agent Pacritinib And New Drug Application In U.S.|
|SEATTLE, Feb. 9, 2016 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today provided an update regarding the clinical studies being conducted under the Company's Investigational New Drug ("IND") application for pacritinib. Following the issuance of the Company's February 8, 2016, press release describing the partial clinical hold issued by the U.S. Food and Drug Administration (FDA) regarding those clinical studies, the Company received an oral communication from the F... |
|Feb 08, 2016||CTI BioPharma Provides Update On Investigational Agent Pacritinib|
|FDA Places Partial Clinical Hold on Pacritinib IND; Currently Enrolled Patients Benefiting from Pacritinib Can Continue Receiving Pacritinib
Phase 3 Clinical Trial (PERSIST-2) Evaluating Pacritinib for Patients with Myelofibrosis and Platelet Counts of ≤100,000/μL has Completed Enrollment
SEATTLE, Feb. 8, 2016 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA:CTIC) today announced that the Company received written communication from the U.S. Food and Drug Administration... |
|Jan 13, 2016||CTI BioPharma Appoints Matthew Perry To Board Of Directors|
|SEATTLE, Jan. 13, 2016 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced that Matthew Perry, President of BVF Partners L.P. (BVF Partners) and CTI BioPharma's largest shareholder, has been appointed to the Board of Directors of CTI BioPharma.
"We are pleased to welcome Matthew Perry from BVF Partners, our largest shareholder, onto our Board at this exciting stage of our company's evolution," commented James A. Bianco, M.D., CTI BioPharma's President a... |
|Jan 11, 2016||CTI BioPharma Announces Positive Progress Of Lead Clinical Programs And General Outlook For Transformational 2016|
|SEATTLE, Jan. 11, 2016 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced positive progress of its lead clinical program in addition to several key business priorities for 2016.
"After a productive 2015, we have entered 2016 well capitalized and focused on preparing for the potential accelerated approval and launch of a new treatment option for people with intermediate and high-risk myelofibrosis with low platelet counts," said James A. Bianco, M.D., CT... |
|Jan 05, 2016||CTI BioPharma And Baxalta Complete Submission Of New Drug Application For Pacritinib For Unmet Medical Need In Myelofibrosis|
|SEATTLE and BANNOCKBURN, Ill., Jan. 5, 2016 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) and Baxalta Incorporated (Baxalta) (NYSE: BXLT) today announced the completion of the rolling submission of the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1 and CSF1R. CTI BioPharma and Baxalta are requesting U.S. marketing approval of pacritinib for the t... |